OMNIPAQUE 300 647 MG
IOHEXOL : 647 MG · DIN 02172747 · GE HEALTHCARE CANADA INC
Health Canada status: MARKETED
What is OMNIPAQUE 300?
OMNIPAQUE 300 647 MG contains IOHEXOL : 647 MG. It is listed in the Health Canada Drug Product Database under DIN 02172747, held by GE HEALTHCARE CANADA INC, supplied as SOLUTION for INTRA-ARTICULAR ; ORAL ; SUBARACHNOIDAL ; INTRAVASCULAR ; RECTAL administration. Health Canada currently lists it as marketed, status dated 03-Jan-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is OMNIPAQUE 300 used for?
Subarachnoid (myelography), Intravascular (angiography, CT enhancement, urography), Arthrography, and Oral/Rectal (GI tract imaging) in adults and pediatrics.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is OMNIPAQUE 300 called?
The same molecule, IOHEXOL, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Omnipaque | Latin | Bahrain, Iceland, Saudi Arabia |
| Illusof | Latin | Bahrain, Saudi Arabia |
| Iohexol PPI | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02172747 |
|---|---|
| Brand name | OMNIPAQUE 300 |
| Generic / active ingredient | IOHEXOL : 647 MG |
| Manufacturer | GE HEALTHCARE CANADA INC |
| Strength | 647 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRA-ARTICULAR ; ORAL ; SUBARACHNOIDAL ; INTRAVASCULAR ; RECTAL |
| Schedule | Ethical |
| ATC code | V08AB02 IOHEXOL |
| AHFS class | 36:68.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 03-Jan-2024 |
| Original market date | 1998-05-26 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02172747 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2172747 |
| Brand name | OMNIPAQUE 300 |
| Active ingredient / INN | IOHEXOL : 647 MG |
| ATC code | V08AB02 |
| ATC anatomical main group | V — Various |
| ATC therapeutic subgroup | V08 |
| AHFS class | 36:68.00 |
| Health Canada schedule | Ethical |
| Biosimilar biologic | No |
| Market authorization holder | GE HEALTHCARE CANADA INC |
How is it administered?
Dosage varies by procedure and age. Administer at body temperature. Subarachnoid: max 3,060 mg iodine in adults. Intravascular: monitor vital signs. Oral/Rectal: used for GI imaging.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Protect from light. (Specific temperature range not in snippet, but standard practice is 15-30°C).
How is it supplied?
Vials and bottles (specific sizes not listed in provided text, but mentions protection from light).
Which pack is which?
| Strength on the label | 647 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRA-ARTICULAR ; ORAL ; SUBARACHNOIDAL ; INTRAVASCULAR ; RECTAL |
| Packaging as described in the monograph | Vials and bottles (specific sizes not listed in provided text, but mentions protection from light). |
| Storage | Protect from light. (Specific temperature range not in snippet, but standard practice is 15-30°C). |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Hypersensitivity to iohexol or any ingredient; clinically significant impairment of both hepatic and renal function.
Warnings and precautions
Risk of serious, life-threatening anaphylactic reactions. Observe patients for 30 mins. Risk of neurological complications if blood-brain barrier is disrupted.
What can be used instead?
Other Canadian products sharing ATC code V08AB02 IOHEXOL. 3 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| OMNIPAQUE 240 | 518 MG | SOLUTION | GE HEALTHCARE CANADA INC | MARKETED | DIN 02172739 |
| OMNIPAQUE 350 | 755 MG | SOLUTION | GE HEALTHCARE CANADA INC | MARKETED | DIN 02172755 |
| OMNIPAQUE 180 | 388 MG | SOLUTION | GE HEALTHCARE CANADA INC | CANCELLED POST MARKET | DIN 02172720 |
| OMNIPAQUE 180 LIQ SAR 388MG/ML | 180 MG | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | DIN 02018098 |
| OMNIPAQUE 240 LIQ IV SAR 518MG/ML | 240 MG | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | DIN 02018101 |
| OMNIPAQUE 300 LIQ IV SAR 647MG/ML | 300 MG | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | DIN 02018128 |
| OMNIPAQUE 350 LIQ IV 755MG/ML | 350 MG | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | DIN 02018136 |
Who else supplies IOHEXOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. IOHEXOL appears in 87 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does IOHEXOL cost around the world?
IOHEXOL is listed on 6 national price registers Nexara tracks, across 71 pack listings published on 6 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Saudi Arabia | public | 6 | 28 | 01 Sep 2026 |
| Hungary | producer price (ex-factory) | 3 | 14 | 03 Sep 2026 |
| Iceland | max wholesale | 1 | 10 | 02 Sep 2026 |
| South Africa | single exit price | 9 | 9 | 01 Sep 2026 |
| Bahrain | retail (max) | 2 | 7 | 01 Sep 2026 |
| Romania | max producer price | 2 | 3 | 03 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.